THE EFFECT OF ADJUVANT CHEMOTHERAPY ON RELAPSE-FREE SURVIVAL IN PATIENTS WITH OSTEOSARCOMA OF THE EXTREMITY
THE EFFECT OF ADJUVANT CHEMOTHERAPY ON RELAPSE-FREE SURVIVAL IN PATIENTS WITH OSTEOSARCOMA OF THE EXTREMITY
复制标题
DOI：
10.1056/nejm198606193142502
复制
发表时间：
1986-06-19
影响因子：
158.5
通讯作者：
VIETTI, TJ
中科院分区：
文献类型：
--
作者：
LINK, MP;GOORIN, AM;VIETTI, TJ
我们进行了一项随机对照试验，以确定与同期对照相比，强化多药辅助化疗是否提高了四肢非转移性高级别骨肉瘤患者的无复发生存机会。在接受了明确的手术后，36名患者被随机分配到辅助化疗或不进行辅助治疗的观察中。两年后，对照组的精算无复发存活率为17%，与1970年之前的研究结果相似，而辅助化疗组的无复发存活率为66%(P<；0.001)。在另外77名拒绝接受随机分组但选择观察或化疗的患者中也观察到了类似的结果。我们的结论是，四肢骨肉瘤的自然病史在过去20年中保持稳定，辅助化疗增加了高级别骨肉瘤患者无复发生存的机会，应该对所有此类患者给予辅助化疗。
We conducted a randomized controlled trial to determine whether intensive multi-agent adjuvant chemotherapy improves the chances of relapse-free survival in patients with nonmetastatic high-grade osteosarcoma of the extremity, as compared with concurrent controls. After undergoing definitive surgery, 36 patients were randomly assigned to adjuvant chemotherapy or to observation without adjuvant treatment. At two years the actuarial relapse-free survival was 17 percent in the control group, similar to that found in studies before 1970, and 66 percent in the adjuvant-chemotherapy group (P < 0.001). Similar results were observed among 77 additional patients who declined to undergo randomization but who elected observation or chemotherapy. We conclude that the natural history of osteosarcoma of the extremity has remained stable over the past two decades, that adjuvant chemotherapy increases the chances of relapse-free survival of patients with high-grade osteosarcoma, and that it should be given to all such patients.